IMGN - ImmunoGen Biosion team up to create antibody-drug conjugates for cancer

• ImmunoGen ( NASDAQ: IMGN ) and Biosion USA are collaborating to create antibody-drug conjugates (ADCs) for treating cancer.
• Under the research team up, Biosion will use its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets chosen by the companies and ImmunoGen will provide its linker-payload technology to create novel ADCs.
• "This collaboration will take advantage of the strengths of each company; ImmunoGen's expertise in linkers and payloads combined with Biosion's SynTracer HT endocytosis platform with the goal of identifying novel treatments for solid tumor cancers," said Biosion President and COO Hugh Davis.

For further details see: